JPRN-UMIN000001531已完成未知
Phase I/II trial of capecitabine plus irinotecan for metastatic breast cancer patient who pretreated with anthracycline and taxane agents - CAPIRI-Breast
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patient have no indication of chemotherapy 2)patient who have priortreated with capecitabine or irinotecan
研究者
相似试验
已完成
1 期
Capecitabine and erlotinib in advanced lung cancerCancerISRCTN18199864Royal Marsden NHS Foundation Trust40
已完成
2 期
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBCBreast Cancer MetastaticNCT00532714National Cancer Center, Korea36
已完成
1 期
Phase I study of a combination of capecitabine plus CPT-11 (CC therapy) in patients with metastatic colon cancer refractory to oxaliplatin containing chemotherapyColorectal cancerJPRN-UMIN000003176Osaka Medical Center for Cancer and Cardiovascular Diseases24
已完成
1 期
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor MalignanciesSolid TumorNCT00215501Dana-Farber Cancer Institute54
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern